The Indian Pharmacopoeia Commission (IPC) recently organised a Scientific Conclave and Interactive Session on Indian Pharmacopoeia (IP) 2026 at the National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad, in collaboration with Central Drugs Standard Control Organization (CDSCO), IDMA Telangana Chapter and NIPER Hyderabad.

The conclave focused on the theme “Significance of Indian Pharmacopoeia Reference Standards and Impurity Standards in Ensuring Pharmaceutical Quality.”

The conclave was organised to deliberate upon the significance of Indian Pharmacopoeia Reference Substances (IPRS) and impurity standards in ensuring the quality, safety, and efficacy of medicines.

The conference was formally inaugurated by Prof. Shailendra Saraf, Director, NIPER Hyderabad, who appreciated IPC for collaborating with academic institutions in advancing pharmaceutical quality initiatives. He highlighted that such collaborations with premier institutions, including NIPER Hyderabad and previously NIPER Ahmedabad, provide an important platform for scientific exchange and capacity building among regulators, academia, and industry stakeholders.

Dr. V. Kalaiselvan, Secretary-cum-Scientific Director, IPC, emphasised that impurity profiling and scientifically established pharmacopoeial standards are essential components in reducing adverse effects associated with pharmaceutical impurities. He reiterated IPC’s commitment toward strengthening medicine quality systems and contributing to the vision of ‘Viksit Bharat’ through robust pharmacopoeial standards and quality assurance mechanisms.

The inaugural session was attended by senior officials from IPC, CDSCO, NIPER Hyderabad, and the pharmaceutical industry.

K. Narendran, Deputy Drugs Controller (India), CDSCO, Hyderabad, also addressed the gathering and highlighted the importance of harmonised standards and regulatory oversight in ensuring medicine quality.

For the first time, IPC brought together experts from regulatory, analytical, industrial, and clinical backgrounds to deliberate upon the clinical implications of pharmacopoeial impurities, including their potential association with Adverse Drug Reactions (ADRs) and patient safety concerns. The conclave also provided an important opportunity for pharmaceutical industries actively involved in the development, adoption, and implementation of IPRS and impurity standards to share their experiences and perspectives.

During the technical sessions, experts deliberated upon contemporary issues related to pharmacopoeial standards, impurity control, regulatory compliance, advancements in IP 2026, impurity reference standards, pharmaceutical quality assurance, risk assessment approaches, and emerging global concerns in pharmaceutical impurity management and regulatory control.

The conclave concluded with an interactive open discussion involving experts from IPC, CDSCO, State Licensing Authorities, academia, clinicians, researchers, and industry representatives on various aspects of pharmaceutical impurities, analytical methodologies, regulatory expectations, and implementation challenges.

The conference was attended by regulators, pharmaceutical industry professionals, academicians, clinicians, analytical scientists, and researchers from across the country, reaffirming IPC’s continued commitment towards strengthening medicine quality systems and promoting public health protection through scientifically robust pharmacopoeial standards.